Journal Scan / Research · December 30, 2020 Disseminated Intravascular Coagulopathy in SJS/TEN International Journal of Dermatology
TAKE-HOME MESSAGE
Among 396 patients with Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) at the Mayo Clinic between July 2012 and January 2020, 5 (1.3%) developed disseminated intravascular coagulopathy (DIC). Of these, 4 patients died, and the fifth was lost to follow-up after a facility transfer.
- Although DIC is an uncommon complication of SJS/TEN, the associated increased mortality risk if patients do have concomitant DIC is substantial. Dermatologists should be aware of this association, and biopsy in SJS/TEN patients in which DIC is a concern should be considered emergent, as demonstration of microthrombi may be helpful in early DIC diagnosis and initiation of interventions such as anticoagulation, dialysis, or other supportive measures.
BACKGROUND
The purpose of this study was to retrospectively assess clinical characteristics and mortality rate of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients who developed disseminated intravascular coagulation (DIC).
METHODS
A systematic retrospective chart review of all patients with concurrent clinical diagnosis of DIC and SJS/TEN between July 1, 2012, and January 1, 2020, at the Mayo Clinic was performed.
RESULTS
The incidence of DIC in patients with SJS/TEN was 1.3% at our institution (5 of 396 DIC patients). Triggers of SJS/TEN included lamotrigine, clofarabine, antibiotics, and sepsis. Two patients diagnosed with SJS and two patients with TEN succumbed to the disease.
CONCLUSION
DIC is a rare underlying risk in patients with SJS/TEN and is associated with increased mortality. Early clinician awareness and aggressive intervention is advised.
International Journal of Dermatology
Disseminated Intravascular Coagulopathy: A Complication of Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis
Int. J. Dermatol 2020 Dec 17;[EPub Ahead of Print], RA El-Azhary, S Nowsheen, LE Gibson, DJ DiCaudo
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home